State of the art: Toward improving outcomes of lung and liver tumor biopsies in clinical trial-a multidisciplinary approach

Elliot B. Levy, Maria I. Fiel, Stanley R. Hamilton, David E. Kleiner, Shannon J. McCall, Peter Schirmacher, William Travis, Michael D. Kuo, Robert D. Suh, Alda L. Tam, Shaheen U. Islam, Katherine Ferry-Galow, Rebecca A. Enos, James H. Doroshow, Hala R. Makhlouf

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Purpose: National Cancer Institute (NCI)-sponsored clinical trial network studies frequently require biopsy specimens for pharmacodynamic and molecular biomarker analyses, including paired pre- and post-treatment samples. The purpose of this meeting of NCI-sponsored investigators was to identify local institutional standard procedures found to ensure quantitative and qualitative specimen adequacy. Methods: NCI convened a conference on best biopsy practices, focusing on the clinical research community. Topics discussed were (1) criteria for specimen adequacy in the personalized medicine era, (2) team-based approaches to ensure specimen adequacy and quality control, and (3) risk considerations relevant to academic and community practitioners and their patients. Results and Recommendations: Key recommendations from the convened consensus panel included (1) establishment of infrastructure for multidisciplinary biopsy teams with a formalized information capture process, (2) maintenance of standard operating procedures with regular team review, (3) optimization of tissue collection and yield methodology, (4) incorporation of needle aspiration and other newer techniques, and (5) commitment of stakeholders to use of guideline documents to increase awareness of best biopsy practices, with the goal of universally improving tumor biopsy practices.

Original languageEnglish (US)
Pages (from-to)1633-1640
Number of pages8
JournalJournal of Clinical Oncology
Issue number14
StatePublished - May 10 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'State of the art: Toward improving outcomes of lung and liver tumor biopsies in clinical trial-a multidisciplinary approach'. Together they form a unique fingerprint.

Cite this